Generate Biomedicines, Inc. Stock Analysis & AI Score
Generate Biomedicines, Inc. (GENB) has an ST Score of 57.3 (B-), driven by its Momentum (A) and held back by its Growth (C-). Analysts rate it Buy with a $26.00 price target (+62.6% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Generate Biomedicines, Inc. (GENB) has an ST Score of 57.3 (B-), driven by its Momentum (A) and held back by its Growth (C-). Analysts rate it Buy with a $26.00 price target (+62.6% upside).
- Strongest
- MomentumA
- Weakest
- GrowthC-
All factor grades
- MomentumA
- ForecastB+
- ValuationB-
- ProfitabilityC+
- Financial StrengthC+
- GrowthC-
Contact
GENB stock: frequently asked questions
What is GENB's ST Score?
Generate Biomedicines, Inc. (GENB) has an ST Score of 57.3 (B-), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is GENB a buy, hold, or sell?
Analysts rate GENB a Buy, with a price target of $26.00 (+62.6% vs the current price). Our ST Score grades it B- (57.3/100). The ST Score is a data-driven signal, not a recommendation.
What are GENB's factor grades?
Valuation B-, Profitability C+, Financial Strength C+, Momentum A, Growth C-, Forecast B+.
What is GENB's valuation grade?
Generate Biomedicines, Inc. (GENB) earns a valuation grade of B-, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is GENB's growth grade?
Generate Biomedicines, Inc. (GENB) earns a growth grade of C-, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is GENB's profitability grade?
Generate Biomedicines, Inc. (GENB) earns a profitability grade of C+, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is GENB's financial strength grade?
Generate Biomedicines, Inc. (GENB) earns a financial strength grade of C+, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for GENB?
The average analyst price target for Generate Biomedicines, Inc. (GENB) is $26.00 from 2 analysts, which is +62.6% versus the recent price of $15.99.